Table 5. Structure–activity relationship of tetrahydropyran–tetrahydrofuran-based protease inhibitors.
Compound Ligand number |
Ki (nM) |
IC50 (nM) |
|
---|---|---|---|
33 | 0.0027 | 0.5 | |
34 | 0.068 | 19 | |
35 | 0.005 | 8 | |
36 | 1.43 | ND | |
37 | 0.11 | ND |
Compound Ligand number |
Ki (nM) |
IC50 (nM) |
|
---|---|---|---|
33 | 0.0027 | 0.5 | |
34 | 0.068 | 19 | |
35 | 0.005 | 8 | |
36 | 1.43 | ND | |
37 | 0.11 | ND |